Andrea Altieri, Chief Scientific Officer, and Diana Zelencova-Gopejenko, Chief Executive Officer, Molport, explore how curated compound libraries—and the platforms that support them—are transforming the landscape of modern screening campaigns in drug discovery. The development of screening libraries has closely followed advances in medicinal chemistry,… Read More
A new App Note is now available for download entitled ‘Powering high-throughput drug screening with Scale Bio‘. Scale Bio’s ScalePlex technology and Single Cell RNA Sequencing Kit v1.1 are revolutionising drug discovery by making large-scale single cell sample and condition screening possible. Libraries from 384 drug conditions were prepared… Read More
Scale Bio’s ScalePlex technology and Single Cell RNA Sequencing Kit v1.1 are revolutionising drug discovery by making large-scale single cell sample and condition screening possible. Libraries from 384 drug conditions were prepared in just 1.5 days 90% reduction in processing time >80% cell recovery rate and >3000 unique transcripts per… Read More
With the cost to sequence genomes declining dramatically, scientists and researchers are applying next generation sequencing (NGS) technology to new discoveries and clinical research applications at a rapidly expanding rate. These applications are driving the need for sample preparation workflows that prepare the DNA/RNA libraries prior to sequencing. A new… Read More
This Scientific Note explores: The benefits of vendor-qualified protocols, incl. reducing start-up process. The three levels of automated library preparation readiness. How fully vendor-qualified libraries enable sequencing in as few as five days. The importance of choosing providers with NGS expertise. Case studies comparing custom vs. vendor-qualified solutions deployment. Read More
Rob Scoffin, CEO, and Matthew Habgood, Principal Computational Chemistry Developer at Cresset, discuss the role of AI/ML in advancing screening methods by utilising virtual screening (VS) approaches to process compound libraries on an ultra-large scale. Drug discovery is a complex process that relies on designing and… Read More
Steve Wowk, VP, Business Unit and General Management of Integrated DNA Technologies, shared with DDW the value of CRISPR-Cas9 in drug discovery. Some of the most important breakthroughs in pharmaceutical research were adapted from naturally occurring phenomena. The CRISPR-Cas9 system, awarded the Nobel Prize in… Read More
The Tecan Group and Oxford Nanopore Technologies will collaborate to drive easier high throughput nanopore library preparation in an automated, hands-free fashion. The aim of the partnership is a fully automated workflow for Oxford Nanopore’s Ligation Sequencing Kit XL V14 protocol (LSK114) with Tecan’s DreamPrep NGS solutions. Read More
X-Chem and Kymera Therapeutics have expanded their collaboration, which will now comprise 12 targets and grants Kymera exclusive rights to compounds discovered within the collaboration. With the expanded agreement, X-Chem will serve as the primary provider of DNA-encoded library (DEL)-based screening services to Kymera – using its… Read More
X-Chem and Sironax have agreed a research partnership, in which X-Chem will use its DEL platform to support Sironax’s drug discovery pipeline. Through the collaboration, X-Chem will screen its DNA-encoded libraries (DEL) against difficult-to-drug targets implicated in neurodegenerative disease to discover hits. In turn, Sironax will prosecute… Read More
Matthew Clark, CEO of X-Chem, looks at what the future could hold for DNA-encoded library (DEL) technology. In the 13 years since it was first described, DNA-encoded library (DEL) technology has become a firmly established approach to small molecule hit generation in drug discovery. Most major pharma companies operate DEL… Read More
Genome engineering company Synthego has launched a portfolio of Engineered Cell Libraries to help improve access to CRISPR-edited cells for direct use in functional screening assays. The company’s Engineered Cell Libraries are designed to provide speed, scalability, and efficiency to accelerate the drug discovery… Read More
More than half of the world’s population is at risk from vector-borne diseases that are transmitted by insects such as mosquitoes, flies and ticks. These diseases cause more than one million deaths annually, and it is primarily people in the poorest countries who are the most vulnerable. Sophia Ktori shares… Read More
NovAliX, a CRO specialising in drug research and development, has partnered with Sanofi for the development of new DNA-Encoded Libraries (DELs), allowing the partners to design both general and focused chemical libraries, and carry out screening activities to identify new and useful chemical structures. Why is this useful? … Read More
Creoptix, a Switzerland-based company focused on next-generation bioanalytical instruments, has launched waveRAPID (Repeated Analyte Pulses of Increasing Duration), a novel, label-free kinetic measurement method that is said to be faster than traditional kinetics. The company developed the Creoptix WAVEsystem to enable molecular interactions to be studied in real time, aimimng… Read More
